AB Science SA (0Q77) AI Stock Analysis

0 Followers

AB Science SA

(LSE:0Q77)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRecent revenue growth indicates that AB Science is generating increasing commercial or collaboration activity despite its early-stage profile. If maintained, expanding revenue can improve operating leverage, support clinical investment, and gradually reduce dependence on external financing over the next several quarters.

Negative Factors

Persistent UnprofitabilityAB Science remains far from breakeven, with recurring operating and net losses despite recent revenue improvement. Continued unprofitability limits internally generated funding, makes earnings quality weak, and increases the importance of successful development, commercialization, or partnering outcomes to establish sustainable economic value.

AB Science SA (0Q77) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 82.04M
Dividend Yield: ―
Average Volume (3M): 2,434
Price to Earnings (P/E): -8.5
Beta (1Y): 0.54
Revenue Growth: 12.66%
EPS Growth: 44.01%
Country: UK
Employees: 33
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

AB Science SA Business Overview & Revenue Model

Company Description

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibit...

AB Science SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0Q77 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:SAN	73Outperform	EUR 103.89B	25.21	5.84%	4.68%	15.30%	-35.58%
FR:IPN	71Outperform	EUR 13.84B	26.93	11.33%	0.96%	13.63%	14.45%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:IPH	47Neutral	EUR 154.82M	-2.60	152.56%	―	-29.48%	7.91%
FR:ALCLS	43Neutral	EUR 97.71M	-2.16	-94.14%	―	-5.98%	-8.67%
FR:OSE	37Underperform	EUR 40.84M	-1.01	-96.73%	―	-96.25%	-197.89%

* Healthcare Sector Average

Performance Comparison

GB:0Q77 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0Q77	Ab Science	0.66	-0.49	-42.26%
FR:IPH	Innate Pharma S.A.	1.33	-0.26	-16.39%
FR:IPN	Ipsen	167.00	36.78	28.25%
FR:OSE	OSE Immunotherapeutics	1.70	-3.89	-69.55%
FR:SAN	Sanofi	87.98	3.13	3.69%
FR:ALCLS	Cellectis SA	1.28	-2.13	-62.41%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AB Science SA AI Stock Analysis